GO
Loading...

GlaxoSmithKline PLC

More

  • An outbreak of Ebola killed close to 10,000 people across West Africa over the last year, with Liberia, Guinea and Sierra Leone being the worst affected. Private company Mapp Biopharmaceutical and Tekmira Pharmaceuticals Corp have shown that their Ebola drugs could cure non-human primates. The other companies that are currently testing potential...

  • NEW YORK, March 30- GlaxoSmithKline Plc has agreed to settle a lawsuit by Johnson& Johnson accusing it of using false advertising at the start of the U.S. allergy season to grab market share. The settlement was disclosed during a hearing in Manhattan federal court on Monday in which two Johnson& Johnson units were expected to ask a judge to block Glaxo from making...

  • J&J, Glaxo settle U.S. lawsuit over allergy ads Monday, 30 Mar 2015 | 6:07 PM ET

    NEW YORK, March 30- GlaxoSmithKline Plc has agreed to settle a lawsuit by Johnson& Johnson accusing it of using false advertising at the start of the U.S. allergy season to grab market share. The settlement was disclosed during a hearing in Manhattan federal court on Monday in which two Johnson& Johnson units were expected to ask a judge to block Glaxo from making...

  • Britain to offer all infants meningitis B vaccine Sunday, 29 Mar 2015 | 12:08 PM ET

    LONDON— Britain says it will become the first country to offer all babies a vaccine for potentially fatal meningitis B after it reached a price deal with GlaxoSmithKline PLC. The drug was owned by Novartis, which recently sold most of its vaccines business to GlaxoSmithKline. Health Secretary Jeremy Hunt said Sunday he was "very proud that we will be the first...

  • March 19- GlaxoSmithKline Plc's drug to treat chronic breathing problems is safe and effective enough to be approved in adults with asthma, but not adolescents, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday. The FDA is not obliged to follow the advice of its advisory panels but typically does so. Glaxo licensed the product from...

  • The FDA is not required to follow the recommendations of its experts, though it often does. Breo Ellipta is already approved in the U.S. for a type of chronic lung disease, but Glaxo is hoping to expand the drug's use to the much larger patient population of roughly 37 million Americans with asthma. In 2010, FDA required manufacturers of LABA-steroid combination...

  • FDA panel to discuss Ebola vaccine development in May Wednesday, 18 Mar 2015 | 8:16 AM ET

    March 18- The U.S. Food and Drug Administration said an advisory panel will discuss the development of Ebola vaccines, days after an American health worker was flown back after being tested positive for Ebola in Sierra Leone. Ebola has so far claimed about 10,000 lives in Sierra Leone, Liberia and Guinea. Other companies that are testing potential treatments for...

  • LONDON, March 17- Other big drugmakers may be reshaping their businesses but Novo Nordisk's focus on diabetes will get even bigger in the coming decade, according to the man most likely to be the Danish company's next boss. Kaare Schultz, who was made deputy chief executive in January 2014 and is the frontrunner to eventually succeed 60- year-old Lars Sorensen,...

  • The review comes two days ahead of a meeting of FDA advisers to discuss the combination treatment, Breo Ellipta, and recommend whether or not it should be approved to treat asthma. The FDA staff said on Tuesday there were no asthma-related deaths in Breo Ellipta studies it reviewed and that data on asthma-related hospitalizations were not observed uniformly...

  • March 17- GlaxoSmithKline Plc's respiratory treatment for chronic breathing problems did not show any new safety problems in treating asthma, a preliminary review by U.S. Food and Drug Administration staff found. The review comes two days ahead of a meeting of FDA advisers to discuss the combination treatment, Breo Ellipta, and recommend whether or not it...

  • *Backers include British govt, GSK, J&J, Pfizer, Lilly, Biogen. Drug companies involved include GlaxoSmithKline, Johnson& Johnson, Eli Lilly, Pfizer and Biogen Idec. The initiative, announced by Britain's health minister Jeremy Hunt at a meeting in Geneva on Tuesday, follows a Group of Eight nations conference in London in December 2013 that set a goal of finding a...

  • LONDON, March 17- The world's first venture capital fund dedicated to finding new ways to prevent and treat dementia has raised $100 million with the backing of the British government and several of the world's leading drugmakers. Drug companies involved include GlaxoSmithKline, Johnson& Johnson, Eli Lilly, Pfizer and Biogen Idec. The initiative, announced by...

  • LONDON, March 16- Scientists are to test a new two-shot Ebola vaccine using an experimental shot from Britain's GlaxoSmithKline, which is already in clinical trials in Africa, and a new kind of booster from Emergent BioSolutions. The Maryland- based biotech company said on Monday its modified vaccinia Ankara Ebola Zaire vaccine would be used in an initial Phase...

  • Europe markets close up; oil in the spotlight Friday, 13 Mar 2015 | 12:42 PM ET

    European equities closed slightly higher Friday, as the oil and gas sector took another hit from tumbling oil prices.

  • NEW YORK, March 12- Johnson& Johnson sued rival drugmaker GlaxoSmithKline PLC on Thursday, alleging that Glaxo is trying to unlawfully grab market share with false advertising at the start of spring allergy season in the United States. Two Johnson& Johnson units, McNeil-PPC Inc and McNeil Consumer Healthcare, filed the lawsuit in U.S. District Court in Manhattan.

  • LONDON, March 12- Pfizer is seeking new vaccine opportunities across the age spectrum as it broadens its portfolio by delivering shots into the arms of adolescents and the elderly, as well as infants. For many years the vaccines industry has been dominated by five big companies, but that has shrunk to four with GlaxoSmithKline's purchase of Novartis' business.

  • GSK's big bet: Tapping our body's electronics Wednesday, 11 Mar 2015 | 5:33 PM ET
    Test tubes and DNA sequence

    GSK expects it can design technology small and smart enough to manipulate our bodies' electrical systems and create new treatments for diseases.

  • LONDON/ GENEVA, March 5- Final stage trials of an Ebola vaccine being developed by Merck and NewLink Genetics will begin in Guinea on March 7, the World Health Organization said on Thursday. Signalling global health authorities' determination to see through trials despite a sharp drop in cases in the West Africa epidemic, the WHO said a second shot, developed by...

  • GENEVA/ LONDON, March 5- Final stage of testing of an experimental Ebola vaccine being developed by Merck and NewLink Genetics will begin in Guinea on March 7, the World Health Organization said on Thursday. All three worst-hit countries- Guinea, Liberia and Sierra Leone- aim to conduct Phase III final-stage clinical trials of experimental vaccines.

  • LONDON, March 4- The idea of using vaccines to fight cancer has received a shot in the arm from a $1 billion deal between Bristol-Myers Squibb and Bavarian Nordic. Unfortunately, they have run into problems in practice, leading to a series of failures with experimental products such as Merck KGaA's Stimuvax and GlaxoSmithKline's MAGE-A3. The idea of combining...